Treatment of Schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2

Human Gene Therapy

Volumn 17, Issue 1, 2006, Pages 20-30

  Messerli, Shanta M ^a   Prabhakar, Shilpa ^a   Tang, Yi ^b   Mahmood, Umar ^b   Weissleder, Ralph ^b   Bronson, Rodrick ^a   Martuza, Robert ^a,b   Rabkin, Samuel ^a,b   Breakefield, Xandra O ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; GENE PRODUCT; HERPESVIRUS VECTOR; MERLIN; ONCOLYTIC VIRUS; PROTEIN; PROTEIN GAMMA34.5; PROTEIN ICP47; PROTEIN S 100; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; HERPES SIMPLEX VIRUS VECTOR; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; MOUSE; NERVE INJURY; NEURILEMOMA; NEUROFIBROMATOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SCHWANN CELL; TRANSGENIC MOUSE; TREATMENT OUTCOME; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ANIMALS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODELS, ANIMAL; DNA, RECOMBINANT; GENE THERAPY; GENETIC VECTORS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEURILEMMOMA; NEUROFIBROMATOSIS 2; SIMPLEXVIRUS;

ANIMALIA; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; MURINAE; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 30744455792     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.20     Document Type: Article

References (51)

1. ADVANI, S.J., WEICHSELBAUM, R.R., WHITLEY, R.J., and ROIZMAN, B. (2002). Friendly fire: Redirecting herpes simplex virus-1 for therapeutic applications. Clin. Microbiol. Infect. 8, 551-563.
2. AHN, K., MEYER, T.H., UEBEL, S., SEMPE, P., DJABALLAH, H., YANG, Y., PETERSON, P.A., FRUH, K., and TAMPE, R. (1996). Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 15, 3247-3255.
3. ALAVI, J.B., and ECK, S.L. (2001). Gene therapy for high grade gliomas. Expert Opin. Biol. Ther. 1, 239-252.
4. ANDREANSKY, S.S., HE, B., GILLESPIE, G.Y., SOROCEANU, L., MARKERT, J., CHOU, J., ROIZMAN, B., and WHITELY, R.J. (1996). The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. U.S.A. 93, 11313-11318.
5. CHAMBERS, R., GILLESPIE, G.Y., SOROCEANU, L., ANDREARSKY, S., CATTERJEE, S., CHOU, J., ROIZMAN, B., and WHITLEY, R.J. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. U.S.A. 92, 1411-1415.
6. CHIOCCA, E.A. (2002). Oncolytic viruses. Nature 2, 938-950.
7. CHOU, J., and ROIZMAN, B. (1992). The γ34.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shut-off of protein synthesis characteristics of programmed cell death in neuronal cells. Proc. Natl. Acad. Sci. U.S.A. 89, 3266-3270.
8. CHOU, I., KERN, E.R., WHITLEY, R.I., and ROIZMAN, B. (1990). Mapping of herpes simplex virus-I neurovirulence to γ34.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
9. COEN, D.M., GOLDSTEIN, D.I., and WELLER S.K. (1989). Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob. Agents Chemother. 33, 1395-1399.
10. ELDRIDGE, R. (1981). Central neurofibromatosis with bilateral acoustic neurons. Adv. Neurol. 29, 57-65.
11. ENDO, T., TODA, M., WATANABE, M., ItZUKA, Y., KUBOTA, T., KITAIIMA, M., and KAWAKAMI, Y. (2002). In situ cancer vaccination with a replication- conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther. 9, 142-148.
12. EVANS, D.G., HUSON, S.M., DONNAI, D., NEARY, W., BLAIR, V., TEARE, D., NEWTON, V., STRACHAN, T., RAMSDEN, R., and HARRIS, R. (1992). A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J. Med. Genet. 29, 841-846.
13. FARASSATI, F., YANG, A.D., and LEE, P.W. (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3, 745-750.
14. FRUH, K., AHN, K., DJABALLAH, H., SEMPE, P., CAN ENDERT, P.M., TAMPE, R., PETERSON, P.A., and YANG, Y. (1995). A viral inhibitor of peptide transporters for antigen presentation. Nature 375, 415-418.
15. GALVE-ROPERH, I., SANCHEZ, C., CORTES, M.L., DEL PULGAR, T.G., IZQUIREDO, M., and GUZMAN, M. (2000). Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-related kinase activation. Nat. Med. 6, 313-319.
16. GIOVANNINI, M., ROBANUS-MAANDAG, E., NIWA-KAWAKITA, M., VAN DER VALK, M., WOODRUFF, J.M., GOUTEBROZE, L., MEREL, P., BERNS, A., and THOMAS, G. (1999). Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev. 13, 978-986.
17. GOLDSTEIN, D.J., and WELLER, S.K. (1988). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62, 196-205.
18. 1, 34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 α to dephosphorylate the α subunit of the eukaryotic translation inhibition factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. U.S.A. 94, 843-848.
19. HILL, A.B., BARNETT, B.C., MCMICHAEL, A.J., and MCGEOCH, D.J. (1994). HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J. Immunol. 152, 2736-2741.
20. HILL, A., JUGOVIC, P., YORK, I., RUSS, G., BENNINK, J., YEWDELL, J., PLOG, H., and JOHNSON, D. (1995). Herpes simplex virus turns off the TAP to evade host immunity. Nature 375, 411-415.
21. HUNG, G., LI, X., FAUDOA, R., XEU, Z., KLUWE, L., RHIM, J.S., SLATTERY, W., and LIM, D. (2002). Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int. J. Oncol. 20, 475-482.
22. HUNTER, W.D., MARTUZA, R.L., FEIGENBAUM, F., TODO, T., MINETA, T., YAZAKI, T., TODA, M., NEWSOME, T.J., PLATENBERG, R.C., MANZ, H.J., and RABKIN, S.D. (1999). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 73, 6319-6326.
23. JENNINGS, S.R., RICE, P.L., KLOSZEWSKI, E.D., ANDERSON, R.W., THOMPSON, D.L., and TEVETHIA, S.S. (1985). Effect of herpes simplex virus types 1 and 2 on surface expression of class I major histocompatibility complex antigens on infected cells. J. Virol. 56, 757-766.
24. JUGOVIC, P., HILL, A.M., TOMAZIN, R., PLOEGH, H.L., and JOHNSON, D. (1998). Inhibition of major histocompatibility complex class I antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47. J. Virol. 72, 5076-5084.
25. KRUSE, C.A., LAMB, C., HOGAN, S., SMILEY, W.R., KLEINSCHMIDT-DEMASTERS, B.K., and BURROWS, F.J. (2000). Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters bystander killing mechanisms. Cancer Gene Ther. 7, 118-127.
26. LEE, J.K., SOBEL, R.A., CHIOCCA, E.A., KIM, T.S., and MARTUZA, R.L. (1992). Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J. Neurosci. 14, 101-112.
27. 1/ SV40 T-antigen transgenic mice. Cancer Res. 65, 1532-1540.
28. LOUIS, D.N., STEMMER-RACHAMIMOV, A.O., and WIESTLER, O.D. (2000). Neurofibromatosis type 2: World Health Organization classification of tumours. In Pathology and Genetics: Tumours of the Nervous System. P. Kleihues and W.K. Cavenee, eds. (IARC Press, Lyon, France) pp. 219-222.
29. MARKERT, J.M., GILLESPIE, G.Y., WEICHSELBAUM, R.R., ROlZMAN, B., and WHITLEY, R.J. (2000). Genetically engineered HSV in the treatment of glioma: Review. Rev. Med. Virol. 10, 17-30.
30. MASHOUR, G.A., MOULDING, H.D., CHAHLAVI, A., KHAN, G.A., RABKIN, S.D., MARTUZA, R.L., DRIEVER, P.H., and KURTZ, A. (2001). Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exp. Neurol. 169, 64-71.
31. MAUTNER, V.F., LINDENAU, M., BASER, M.E., HAZIM, W., TATAGIBA, M., HAASE, W., SAMII, M., WAIS, R., and PULST, S.M. (1996). The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 38, 880-885.
32. MCCLATCHEY, A.I., SAOTOMA, I., MERCER, K., CROWLEY, D., GUSELLA, J.F., BRONSON, R.T., and JACKS, T. (1998). Mice heterozygous for a mutation at the NF2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12, 1121-1133.
33. MCKIE, E.A., MACLEAN, A.R., LEWIS, A.D., CRUICKSHANK, G., RAMPLING, R., BARNETT, S.C., KENNEDY, P.O., and BROWN, S.M. (1996). Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumors: Evaluation of a potentially effective clinical therapy. Br. J. Cancer 74, 745-752.
34. MESSERLI, S.M., TANG, Y., GIOVANNINI, M., BRONSON, R., WEISSLEDER, R., and BREAKEFIELD, X.O. (2002). Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia 4, 501-509.
35. MINETA, T., RABKIN, S.D., YAZAKI, T., HUNTER, W.D., and MARTUZA, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938-943.
36. NAKANO, K., TODO, T., CHIJIIWA, K., and TANAKA, M. (2001). Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol. Ther. 3, 431-437.
37. PARRY, D.M., ELDRIDGE, R., KAISER-KUPFER, M.I., BOUZAS, E.A., PIKUS, A., and PATRONAS, N. (1994). Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am. J. Med. Genet. 52, 450-461.
38. PETROWSKY, H., ROBERTS, G.D., KOOBY, D.A., BURT, B.M., BENNETT, J.J., DELMAN, K.A., STANZIALE, S.F., DELOHERY, T.M., TONG, W.P., FEDEROFF. H.J., and FONG, Y. (2001). Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J. Virol. 75, 7050-7058.
39. ROULEAU, G.A., MEREL, P., LUTCHMAN, M., SANSON, M., ZUCMAN, J., MARINEAU, C., HOANG-XUAN, K., DEMCZUK, S., DESMAZE, C., and PLOUGASTEL, B. (1993). Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363, 515-521.
40. SAEKI, Y., BREAKEFIELD, X.O., and CHIOCCA, E.A. (2003). Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol. Med. 76, 51-60.
41. SHORT, M.P., RICHARDSON, E.P.J., HAINES, J.L., and KWIATKOWSKI, D.J. (1995). Clinical, neuropathological and genetic aspects of the tuberous sclerosis complex. Brain Pathol. 5, 173-179.
42. STEMMER-RACHAMIMOV, A., LOUIS, D.N., NIELSEN, G.P., ANTONESCU, C., BOROWKSY, A., BRONSON, R., BURNS, O.K., CERVERA, P., MCLAUGHLIN, M., REIFENBERGER, G., SCHMALE, M., MACCOLLIN, M., CHAO, R., CICHOWSKI, K., KALAMARIDES, M., MESSERLI, S.M., MCCLATCHEY, A., NIWA-KAWAKITA, M., RATNER, N., REILLY, K., ZHU, Y., and GIOVANNINI, M. (2004). Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res. 64, 3718-3724.
43. SUNDARESAN, P., HUNTER, W.D., MARTUZA, R.L., and RABKIN, S.D. (2000). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice. J. Virol. 74, 3832-3841.
44. TODA, M., RABKIN, S.D., KOJIMA, H., and MARTUZA, R.L. (1999). Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 10, 385-393.
45. TODA, M., IIZUKA, Y., KAWASE, T., UYEMURA, K., and KAWAKAMI, Y. (2002). Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther. 9, 356-364.
46. TODO, T., RABKIN, S.D., SUNDARESAN, P., WU, A., MEEHAN, K.R., HERSCOWITZ, H.B., and MARTUZA, R.L. (1999). Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. 10, 2741-2755.
47. TODO, T., MARTUZA, R.I., RABKIN, S.D., and JOHNSON, P.A. (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. U.S.A. 98, 6396-6401.
48. TOME, W.A., MEHTA, M.P., MEEKS, S. L., and BUATTI, J.M. (2002). Fractionated stereotactic radiotherapy: A short review. Technol. Cancer Res. Treatment 1, 153-172.
49. VARGHESE, S., and RABKIN, S.D. (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9, 967-978.
50. VARGHESE, S., NEWSOME, J.T., RABKIN, S.D., MCGEAGH, K., MAHONEY, D., NIELSEN, P., TODO, T., and MARTUZA, R.L. (2001). Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum. Gene Ther. 12, 999-1010.
51. + T lymphocytes. Cell 77, 525-535.